Cypress Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.38 Cr
- Paid Up Capital ₹ 1.30 Cr
- Company Age 7 Year, 11 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth -83.81%
- Profit Growth -19.95%
- Ebitda -20.18%
- Net Worth -118.92%
- Total Assets -51.43%
About Cypress Pharmaceuticals
Cypress Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 March 2017 (Seven years and 11 months 2 days old ). Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.38 Cr and a paid-up capital of Rs 1.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Lav Kumar and Rakesh Ranjan serve as directors at the Company.
Company Details
-
Location
Thane, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999MH2017PTC292146
-
Company No.
292146
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Mar 2017
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Cypress Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lav Kumar
|
Director | Current | |
|
Rakesh Ranjan
|
Director | 26-Aug-2019 | Current |
Financial Performance of Cypress Pharmaceuticals.
Cypress Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 83.81% decrease. The company also saw a substantial fall in profitability, with a 19.95% decrease in profit. The company's net worth observed a substantial decline by a decrease of 118.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cypress Pharmaceuticals?
In 2020, Cypress Pharmaceuticals had a promoter holding of 7.52% and a public holding of 92.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Gayatriindia Bhavishya Nidhi LimitedLav Kumar and Rakesh Ranjan are mutual person
-
Gayatri Nidhi Limited
Lav Kumar and Rakesh Ranjan are mutual person
-
Ebony Products Private Limited
Lav Kumar and Rakesh Ranjan are mutual person
-
Winnet Nidhi Limited
Rakesh Ranjan is a mutual person
-
Winnet Mutual Nidhi Limited
Rakesh Ranjan is a mutual person
-
Winnet Realcon Private Limited
Rakesh Ranjan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cypress Pharmaceuticals?
Unlock and access historical data on people associated with Cypress Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cypress Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cypress Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
